Gangrene, hearing loss point to Covid-19 Delta strain being more severe

The variant, also known as B.1.617.2, was the 'primary cause' behind India's deadlier second wave, according to a government panel.

covid deaths
A woman mourns after her husband died due to the coronavirus disease outside a mortuary of a COVID-19 hospital in Ahmedabad (Photo: Reuters)
Bhuma Shrivastava | Bloomberg
5 min read Last Updated : Jun 08 2021 | 5:54 AM IST
The coronavirus variant that drove India’s devastating Covid-19 epidemic is the most infectious to emerge so far. Doctors now want to know if it’s also more severe.

Hearing impairment, severe gastric upsets and blood clots leading to gangrene, symptoms not typically seen in Covid patients, have been linked by doctors in India to the so-called Delta variant. In England and Scotland, early evidence suggests the now-dominant strain carries a higher risk of hospitalization.

Delta, also known as B.1.617.2, has spread to more than 60 countries over the past six months and triggered travel curbs from Australia to the U.S. A spike in infections, fueled by the Delta variant, has put pressure on the U.K. government to reconsider its plans of reopening later this month. Higher rates of transmission compared with other variants, and a reduction in the effectiveness of vaccines, have made understanding the strain’s effects especially critical.


“We need more scientific research to analyze if these newer clinical presentations are linked to B.1.617 or not,” said Abdul Ghafur, an infectious disease physician at the Apollo Hospital in Chennai, southern India’s largest city. Ghafur said he is seeing more Covid-19 patients with diarrhea now than in the initial wave of the epidemic.

‘New enemy’

“Last year, we thought we had learned about our new enemy, but it changed,” Ghafur said. “This virus has become so, so unpredictable.”

Stomach pain, nausea, vomiting, loss of appetite, hearing loss and joint pain are among the ailments Covid-19 patients are experiencing, according to six doctors treating patients across India. Beta and Gamma variants--first detected in South Africa and Brazil respectively--have shown little or no evidence of producing different clinical signs, according to a study by researchers from University of New South Wales last month.

Some patients develop micro thrombi, or small blood clots, so severe that they led affected tissue to die and develop gangrene, said Ganesh Manudhane, a Mumbai cardiologist, who has treated eight patients for thrombotic complications at the Seven Hills Hospital during the past two months. Two required amputations of fingers or a foot.

“I saw three-to-four cases the whole of last year, and now it’s one patient a week,” Manudhane said.

Baffling clots

India has reported 18.6 million Covid-19 cases thus far in 2021, compared with 10.3 million last year. The Delta variant was the “primary cause” behind the country’s deadlier second wave and is 50% more contagious than the Alpha strain that was first spotted in the U.K., according to a recent study by an Indian government panel.

The surge in cases may have driven an increase in the frequency with which rare Covid-19 complications are being observed. Even still, Manudhane said he is baffled by the blood clots he’s seeing in patients across age groups with no past history of coagulation-related problems.


“We suspect it could be because of the new virus variant,” he said. Manudhane is collecting data to study why some people develop the clots and others don’t.

Doctors are also finding instances of clots forming in blood vessels that supply the intestines, causing patients to experience stomach pain -- their only symptom, local media have reported.

Some Covid patients are also seeking medical care for hearing loss, swelling around the neck and severe tonsillitis, said Hetal Marfatia, an ear nose and throat surgeon at Mumbai’s King Edward Memorial Hospital.

“Every person is showing different symptoms” in the second wave, she said.

‘Atypical presentations’

The unusual presentations for Delta and a closely related variant known as Kappa, whose spread led to a fourth lockdown in Melbourne, are still being confirmed, said Raina MacIntyre, a professor of global biosecurity at the University of New South Wales in Sydney. “In the meanwhile, it is important to take note of this and be aware of possible atypical presentations,” she said.

The most alarming aspect of the current epidemic in India is the rapidity with which the virus is spreading, including to children, said Chetan Mundada, a pediatrician with the Yashoda group of hospitals in Hyderabad.

Apollo’s Ghafur said he was also seeing entire families with Covid symptoms, instead of the individuals that dominated last year, reflecting an increase in household transmission caused by the Delta variant.

Cases of Mucormycosis -- a rare opportunistic fungal infection -- have also been surging in India. It had infected more than 8,800 Covid patients and survivors as of May 22, forcing local health care authorities to call it an epidemic.


Even as India’s outbreak begins to ease -- daily infections have slipped to about a quarter of the May 7 peak -- Delta has sparked outbreaks elsewhere, including virus havens such as Taiwan, Singapore and Vietnam, bolstering calls for mass immunization.

But with emerging evidence Delta and at least one other variant may be adept at evading vaccine-induced antibodies, pharmaceutical companies are under pressure to tweak existing shots or develop new ones.

“New vaccines have to prepared with new variants in mind,” said Ghafur. “We can’t get ahead of the virus, but at least we can least keep up with it.”

(With assistance from P R Sanjai.)

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story